Big pharma against CL move but WHO agrees


Right to get treatment: It was reported last year that there were 400,000 Hepatitis C sufferers in Malaysia, with only a fraction who could afford the RM300,000 cost. — AFP

KUALA LUMPUR: Malaysia’s bold move to impose compulsory licence (CL) on the drug sofosbuvir has been heavily criticised by big pharmaceutical companies, but has the support of the World Health Organisation (WHO).

WHO advocates universal health coverage and that means access to life-saving treatment, said its head of mission and representative to Malaysia, Brunei and Singapore Dr Lo Ying-Ru.

The Star Christmas Special Promo: Save 35% OFF Yearly. T&C applies.

Monthly Plan

RM 13.90/month

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Nation

Royal addendum decision raises serious constitutional issues, says MCA Youth
Open sewerage hole at construction site raises safety concerns after Sandakan crash
Mersing man missing, feared drowned after boat capsizes on fishing trip
Due process must take place, says Khaled on money laundering allegations against military officer
King arrives safely in Abu Dhabi for special visit to UAE
Perlis assembly may be in limbo after several reps allegedly withdraw support for MB
Expert says Najib house arrest ruling is constitutional
Asean must do what is necessary to maintain regional peace, says Malaysia FM
Umno leaders call out Puchong MP over remark on decision in Najib's house arrest bid
Cops find three makeshift bombs in Nilai apartment

Others Also Read